McKesson Raises FY26 Non-GAAP EPS Outlook Following Strong Q3 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy MCK?
Source: seekingalpha
- Strong Financial Performance: McKesson's Q3 non-GAAP EPS reached $9.34, a 16% increase from $8.03 in the prior year, exceeding market expectations by $0.07, indicating robust performance in the drug wholesale sector.
- Upgraded Outlook: The company raised its FY26 non-GAAP EPS forecast to $38.80-$39.20, up from $38.35-$38.85, reflecting increased confidence in future earnings.
- North American Growth: The growth in Q3 results was primarily driven by the North American Pharmaceutical segment, particularly due to increased prescription volumes from retail national account customers and distribution growth of oncology and multispecialty products, further solidifying market position.
- Cash Flow Status: As of the end of FY25, McKesson had approximately $3 billion in cash and cash equivalents, down from $5.7 billion on March 31, 2025, indicating the company's strategic approach to fund management in investments and operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MCK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MCK
Wall Street analysts forecast MCK stock price to rise
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 916.000
Low
880.00
Averages
942.83
High
1000.00
Current: 916.000
Low
880.00
Averages
942.83
High
1000.00
About MCK
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Rebounds as Eli Lilly Prepares for New Drug Launch
- Market Rebound: After a volatile week, the S&P 500 showed signs of recovery on Friday, although it still faced losses over the past five trading days, indicating a renewed investor confidence in the economic outlook.
- Inflation Data Impact: The cooler-than-expected January consumer price index contributed to a drop in bond yields and increased expectations for interest rate cuts later this year, further bolstering investor sentiment.
- Eli Lilly's Drug Inventory: Eli Lilly has built up $1.5 billion worth of pre-launch inventory for its GLP-1 obesity pill orforglipron, significantly up from $550 million last year, indicating strong demand expectations from the market.
- Upcoming Earnings Reports: Approximately 50 S&P 500 companies are set to report earnings next week, including Palo Alto Networks and Texas Roadhouse, with the market closely watching these reports for their implications on the broader economy.
See More
Becton, Dickinson and Company Stock in Focus
- Intensifying Market Competition: Becton, Dickinson faces fierce competition in the medical device distribution sector, particularly as Boston Scientific's dominance in the pulse field ablation market is challenged, indicating that changing market dynamics could impact the company's performance.
- Investment Potential Assessment: While Becton, Dickinson is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, implying that investors should be cautious in their selections.
- Diverse Medical Supply Portfolio: Becton, Dickinson sells a significant variety of medical supplies, diagnostic tools, and lab equipment, widely used by healthcare professionals and researchers, highlighting its importance and demand in the healthcare industry.
- Market Dynamics Observation: Jim Cramer expresses a bullish view on Becton, Dickinson, suggesting that its performance in the medical device sector is worth monitoring, reflecting investor optimism about the company's future prospects.
See More
Healthcare Stocks Shine with McKesson Up 16.6%
- Healthcare Sector Performance: In Thursday's trading, healthcare stocks emerged as the best-performing sector, rising by 0.2%, with McKesson Corp (MCK) leading the charge with a 16.6% gain, indicating strong market demand that could attract more investor interest in the sector.
- Cardinal Health's Gains: Cardinal Health, Inc. (CAH) also performed well, with a 9.0% increase, suggesting a solid position in the healthcare supply chain that may further enhance its market share and investor confidence.
- ETF Trends: Despite the overall positive performance in healthcare, the Health Care Select Sector SPDR ETF (XLV) fell by 0.5%, indicating a preference for individual stocks over ETFs, which may lead to a shift in capital towards more promising equities.
- Utilities Sector Stability: The utilities sector showed relative stability, with CMS Energy Corp (CMS) up 2.4% and PPL Corp (PPL) up 1.4%, reflecting investor preference for stable returns, which may attract more capital into this sector in the future.
See More
US Stocks Plunge as Tech Sector Leads Decline
- Tech Sector Decline: Qualcomm's (QCOM) forecast of weaker-than-expected Q2 revenue led to an over 8% drop in its stock, triggering a sell-off across the tech sector, with the Nasdaq 100 index hitting a 2.5-month low, indicating waning investor confidence in technology stocks.
- Weak Labor Market Signals: Challenger's report revealed a staggering 117.8% year-over-year increase in job cuts for January, totaling 108,435, the highest for January since 2009, while initial jobless claims rose by 22,000 to 231,000, highlighting vulnerabilities in the US labor market that could hinder economic recovery.
- Bitcoin Plunge: Bitcoin (^BTCUSD) plummeted over 12% to a 1.25-year low, reflecting deepening negative momentum in the cryptocurrency market, with approximately $2 billion flowing out of Bitcoin ETFs in the past month, signaling a decline in investor confidence.
- Earnings Season Impact: Despite 150 S&P 500 companies set to report earnings this week, market focus on economic data intensifies, with S&P 500 earnings expected to grow by 8.4% in Q4, yet overall market sentiment remains suppressed by recent economic weakness.
See More
Mullin's Small-Cap Stock Investments Update
- Stock Purchase Overview: On January 5, 2026, Mullin disclosed purchases of 10 stocks, each ranging from $15,000 to $50,000, indicating his ongoing interest in small and mid-cap stocks, with most having market capitalizations below $20 billion.
- Small-Cap Characteristics: Notably, two of these stocks have market caps under $5 billion, reinforcing Mullin's preference for smaller stocks, which could influence his decisions on the Armed Services Committee, particularly regarding future government contracts.
- Historical Trade Review: Prior to this, on December 29, 2025, Mullin bought six of the Magnificent Seven stocks, investing at least $50,000, highlighting his preference for tech stocks, with Microsoft Corp (MSFT) being the largest investment.
- Potential Conflict of Interest: Given Mullin's role on the Armed Services Committee, Benzinga will closely monitor his future stock trades, especially concerning potential conflicts arising from military actions in countries like Venezuela.
See More
Stocks Shift to Negative Territory for the Year
- Market Performance: The S&P 500 index declined for the third consecutive day, dropping by 1.2%.
- Year-to-Date Status: This decline has pushed the index into negative territory for the year.
See More
Market Rebounds as Eli Lilly Prepares for New Drug Launch
- Market Rebound: After a volatile week, the S&P 500 showed signs of recovery on Friday, although it still faced losses over the past five trading days, indicating a renewed investor confidence in the economic outlook.
- Inflation Data Impact: The cooler-than-expected January consumer price index contributed to a drop in bond yields and increased expectations for interest rate cuts later this year, further bolstering investor sentiment.
- Eli Lilly's Drug Inventory: Eli Lilly has built up $1.5 billion worth of pre-launch inventory for its GLP-1 obesity pill orforglipron, significantly up from $550 million last year, indicating strong demand expectations from the market.
- Upcoming Earnings Reports: Approximately 50 S&P 500 companies are set to report earnings next week, including Palo Alto Networks and Texas Roadhouse, with the market closely watching these reports for their implications on the broader economy.
See More
Becton, Dickinson and Company Stock in Focus
- Intensifying Market Competition: Becton, Dickinson faces fierce competition in the medical device distribution sector, particularly as Boston Scientific's dominance in the pulse field ablation market is challenged, indicating that changing market dynamics could impact the company's performance.
- Investment Potential Assessment: While Becton, Dickinson is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, implying that investors should be cautious in their selections.
- Diverse Medical Supply Portfolio: Becton, Dickinson sells a significant variety of medical supplies, diagnostic tools, and lab equipment, widely used by healthcare professionals and researchers, highlighting its importance and demand in the healthcare industry.
- Market Dynamics Observation: Jim Cramer expresses a bullish view on Becton, Dickinson, suggesting that its performance in the medical device sector is worth monitoring, reflecting investor optimism about the company's future prospects.
See More
Healthcare Stocks Shine with McKesson Up 16.6%
- Healthcare Sector Performance: In Thursday's trading, healthcare stocks emerged as the best-performing sector, rising by 0.2%, with McKesson Corp (MCK) leading the charge with a 16.6% gain, indicating strong market demand that could attract more investor interest in the sector.
- Cardinal Health's Gains: Cardinal Health, Inc. (CAH) also performed well, with a 9.0% increase, suggesting a solid position in the healthcare supply chain that may further enhance its market share and investor confidence.
- ETF Trends: Despite the overall positive performance in healthcare, the Health Care Select Sector SPDR ETF (XLV) fell by 0.5%, indicating a preference for individual stocks over ETFs, which may lead to a shift in capital towards more promising equities.
- Utilities Sector Stability: The utilities sector showed relative stability, with CMS Energy Corp (CMS) up 2.4% and PPL Corp (PPL) up 1.4%, reflecting investor preference for stable returns, which may attract more capital into this sector in the future.
See More
US Stocks Plunge as Tech Sector Leads Decline
- Tech Sector Decline: Qualcomm's (QCOM) forecast of weaker-than-expected Q2 revenue led to an over 8% drop in its stock, triggering a sell-off across the tech sector, with the Nasdaq 100 index hitting a 2.5-month low, indicating waning investor confidence in technology stocks.
- Weak Labor Market Signals: Challenger's report revealed a staggering 117.8% year-over-year increase in job cuts for January, totaling 108,435, the highest for January since 2009, while initial jobless claims rose by 22,000 to 231,000, highlighting vulnerabilities in the US labor market that could hinder economic recovery.
- Bitcoin Plunge: Bitcoin (^BTCUSD) plummeted over 12% to a 1.25-year low, reflecting deepening negative momentum in the cryptocurrency market, with approximately $2 billion flowing out of Bitcoin ETFs in the past month, signaling a decline in investor confidence.
- Earnings Season Impact: Despite 150 S&P 500 companies set to report earnings this week, market focus on economic data intensifies, with S&P 500 earnings expected to grow by 8.4% in Q4, yet overall market sentiment remains suppressed by recent economic weakness.
See More
Mullin's Small-Cap Stock Investments Update
- Stock Purchase Overview: On January 5, 2026, Mullin disclosed purchases of 10 stocks, each ranging from $15,000 to $50,000, indicating his ongoing interest in small and mid-cap stocks, with most having market capitalizations below $20 billion.
- Small-Cap Characteristics: Notably, two of these stocks have market caps under $5 billion, reinforcing Mullin's preference for smaller stocks, which could influence his decisions on the Armed Services Committee, particularly regarding future government contracts.
- Historical Trade Review: Prior to this, on December 29, 2025, Mullin bought six of the Magnificent Seven stocks, investing at least $50,000, highlighting his preference for tech stocks, with Microsoft Corp (MSFT) being the largest investment.
- Potential Conflict of Interest: Given Mullin's role on the Armed Services Committee, Benzinga will closely monitor his future stock trades, especially concerning potential conflicts arising from military actions in countries like Venezuela.
See More
Stocks Shift to Negative Territory for the Year
- Market Performance: The S&P 500 index declined for the third consecutive day, dropping by 1.2%.
- Year-to-Date Status: This decline has pushed the index into negative territory for the year.
See More
